Antimicrobial resistance: Charles Darwin was right; India’s drug policy isn’t Premium

Explore how India's drug policy fails to address antimicrobial resistance as an evolutionary consequence of antibiotic use and governance.

Charles Darwin’s central insight wasn’t just that species evolve but that they can’t but adapt in the presence of selection pressures. In practical terms, organisms don’t choose to change: they respond to the environments in which they’re trying to live. This insight should trouble us when we consider antimicrobial resistance (AMR): because resistance isn’t an anomaly of the antibiotic era — it is a logical consequence.

For many decades, we have governed antibiotics as static medical tools: prescribed to individuals, regulated largely by access and volume, and evaluated using short-term clinical outcomes. So when resistance emerged, we treated it as a breakdown of stewardship, compliance, and/or enforcement. Yet in the biological sense, resistance is not a failure of use. It’s the expected outcome of using antibiotics at scale.

Antibiotics aren’t only pharmacological agents: they are evolutionary interventions that reshape microbial populations wherever they’re deployed. Every antibiotic dose is a selective event. It means each time you take an antibiotic, you create a strong evolutionary pressure in your body and its surroundings. Bacteria that are susceptible are killed or suppressed while those that can resist survive and multiply. Repeating the antibiotic doses amplifies this selection, increasing the share of resistant strains.

Every clinic, hospital, farm, and wastewater outlet becomes a place where microbial populations are shaped by survival advantage. The problem is not that evolution is surprising but that our health systems continue to behave as though it can be ignored.

Bacteria also adapt on timescales that governance does not. Mutations arise within hours. Resistant strains circulate within days. Surveillance updates, treatment guidelines, and regulatory responses unfold over years. This structural lag ensures resistance becomes visible only after it has become widespread.

In India, this lag is most evident in everyday care, including crowded outpatient clinics, district hospitals with limited laboratory support, and private practices under pressure to act quickly. In settings where rapid, affordable diagnostics are unavailable, antibiotics often substitute for testing instead of complementing it.